Volker Wagner

Chief Medical Officer OranoMed

Seminars

Wednesday 12th November 2025
Expanding TRP Therapy into Neuroendocrine Tumours: Targeting SSTR2 with 212Pb
4:00 pm
  • Discussing Orano Med’s unique approach to TAT with 212Pb
  • Presenting the latest updates on 212Pb-DOTAMTATE 
  • Exploring Orano Med’s portfolio of 212Pb-based TATs
Volker Wagner, Chief Medical Officer, OranoMed